Table 1 EBV carriage renders the cells more sensitive to inhibition of MTH1

From: The Epstein–Barr virus nuclear antigen-1 upregulates the cellular antioxidant defense to enable B-cell growth transformation and immortalization

% Apoptotic cellsa

Fold changef

Cell lines

EBVb

Control

TH588c

S-crizotinibd

TH588

S-crizotinib

BJAB

−

7.7 ± 1.7

12.2 ± 0.1

15.6 ± 1.4

1.6

2.0

BJAB-B958

+

8.1 ± 4.1

32.7 ± 3.4

39.9 ± 1.4

4.0

4.9

BL41

−

5.4 ± 1.0

19.3 ± 4.4

22.9 ± 4.7

3.6

4.3

BL41-E95B

+

14.8 ± 5.5

88.0 ± 4.0

94.5 ± 0.9

6.0

6.4

Akata

−

4.8 ± 1.1

30.3 ± 2.3

11.7 ± 3.8

6.3

2.4

Akata-BX1

+

3.2 ± 1.5

51.9 ± 2.9

7.0 ± 1.2

16.4

2.2

AGS

−

1.6 ± 0.2

14.3 ± 2.7

3.8 ± 0.3

8.9

2.4

AGS-BX1

+

1.7 ± 0.8

26.5 ± 0.9

11.2 ± 0.5

15.3

6.5

TWO3

−

9.8 ± 1.7

27.6 ± 4.6

19.2 ± 2.4

2.8

2.0

TWO3-EBV

+

12.5 ± 4.5

25.6 ± 1.7

54.7 ± 7.0

2.0

4.4

 

eEBNA1

     

BJAB

−

7.7 ± 1.7

12.2 ± 0.1

15.6 ± 1.4

1.6

2.0

BJAB-EBNA1

+

4.8 ± 1.0

31.4 ± 2.8

21.7 ± 2.5

6.5

4.5

BJAB-tTAE1 Dox+

−

9.0 ± 2.5

19.6 ± 0.2

23.8 ± 1.0

2.2

2.7

BJAB-tTAE1 Dox-

+

9.7 ± 2.3

40.4 ± 1.2

48.1 ± 0.8

4.2

5.0

  1. Values corresponding to ≥ 50% increased apoptosis in EBV/EBNA1 positive cells are underlined
  2. aApoptosis was measured by staining with PI/Annexin-V and flow cytometry analysis. The mean ± SD positive cells in two independent experiments is shown
  3. bEBV carriage was in all cases confirmed by detection of EBNA1
  4. cThe cells were treated with 10 μM TH588 for 48 h
  5. dThe cells were treated with 5 μM S-Crizotinib for 48 h
  6. eEBNA1 expression was confirmed by western blot analysis
  7. f Fold change was calculated as the ratio between the mean % apoptotic cells in control and treated cells
Back to article page